| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.
|
N Engl J Med
|
2015
|
10.86
|
|
2
|
Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
|
Chest
|
2012
|
5.99
|
|
3
|
Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
|
Chest
|
2012
|
5.57
|
|
4
|
Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial.
|
Ann Intern Med
|
2009
|
5.48
|
|
5
|
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
|
Chest
|
2012
|
5.27
|
|
6
|
Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
|
Chest
|
2012
|
5.02
|
|
7
|
Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials.
|
BMJ
|
2011
|
3.28
|
|
8
|
Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis.
|
Lancet
|
2006
|
3.25
|
|
9
|
Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
|
Chest
|
2012
|
3.14
|
|
10
|
Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
|
Chest
|
2012
|
2.83
|
|
11
|
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
|
Circulation
|
2013
|
2.72
|
|
12
|
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.
|
Ann Intern Med
|
2015
|
2.63
|
|
13
|
Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
|
Chest
|
2012
|
2.55
|
|
14
|
Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
|
Chest
|
2004
|
2.50
|
|
15
|
Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients.
|
Anesthesiology
|
2014
|
2.12
|
|
16
|
Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial.
|
Ann Intern Med
|
2013
|
2.09
|
|
17
|
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.
|
Blood
|
2010
|
1.89
|
|
18
|
The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism.
|
Ann Intern Med
|
2007
|
1.63
|
|
19
|
Periprocedural Management of Direct Oral Anticoagulants: Comment on the 2015 American Society of Regional Anesthesia and Pain Medicine Guidelines.
|
Reg Anesth Pain Med
|
2016
|
1.60
|
|
20
|
Is the network meta-analysis (NETMA) bringing us closer to the truth? Insights from recent antithrombotic drug data.
|
Thromb Haemost
|
2012
|
1.37
|
|
21
|
Cervical artery dissection: pathology, epidemiology and management.
|
Thromb Res
|
2009
|
1.33
|
|
22
|
Optimal timing of resumption of warfarin after intracranial hemorrhage.
|
Stroke
|
2010
|
1.19
|
|
23
|
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention.
|
Am J Hematol
|
2009
|
1.11
|
|
24
|
Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2002
|
1.11
|
|
25
|
Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy.
|
Thromb Res
|
2011
|
1.03
|
|
26
|
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model.
|
Blood
|
2010
|
0.97
|
|
27
|
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
|
Circ Cardiovasc Qual Outcomes
|
2010
|
0.96
|
|
28
|
Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations.
|
Thromb Haemost
|
2008
|
0.93
|
|
29
|
Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis.
|
Can J Cardiol
|
2013
|
0.92
|
|
30
|
Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.
|
Clin Pharmacol Ther
|
2005
|
0.92
|
|
31
|
Platelet-leukocyte aggregation under shear stress: differential involvement of selectins and integrins.
|
Thromb Haemost
|
2003
|
0.89
|
|
32
|
Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators.
|
Pacing Clin Electrophysiol
|
2009
|
0.87
|
|
33
|
Thrombosis is associated with inferior survival in multiple myeloma.
|
Haematologica
|
2012
|
0.86
|
|
34
|
Bleeding and antidotes in new oral anticoagulants.
|
Best Pract Res Clin Haematol
|
2013
|
0.84
|
|
35
|
Respiratory review of 2013: pulmonary thromboembolism.
|
Tuberc Respir Dis (Seoul)
|
2013
|
0.82
|
|
36
|
Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study.
|
Thromb Haemost
|
2012
|
0.81
|
|
37
|
Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy.
|
Thromb Haemost
|
2012
|
0.81
|
|
38
|
Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
|
Blood Coagul Fibrinolysis
|
2007
|
0.81
|
|
39
|
Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Results of a prospective cohort study.
|
Thromb Haemost
|
2010
|
0.81
|
|
40
|
Acquired hemophilia masked by warfarin therapy: report on two cases.
|
Blood Coagul Fibrinolysis
|
2003
|
0.80
|
|
41
|
Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance.
|
Semin Hematol
|
2011
|
0.80
|
|
42
|
Limited protective effect of the CCR5Delta32/CCR5Delta32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus.
|
J Infect Dis
|
2003
|
0.80
|
|
43
|
Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices.
|
J Thromb Thrombolysis
|
2014
|
0.80
|
|
44
|
Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report.
|
J Thromb Thrombolysis
|
2015
|
0.80
|
|
45
|
Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II.
|
Thromb Haemost
|
2016
|
0.80
|
|
46
|
Accuracy and safety of (99m)Tc-labeled anti-D-dimer (DI-80B3) Fab' fragments (ThromboView®) in the diagnosis of deep vein thrombosis: a phase II study.
|
Thromb Res
|
2012
|
0.79
|
|
47
|
High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients.
|
Thromb Haemost
|
2013
|
0.79
|
|
48
|
A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery.
|
Thromb Haemost
|
2010
|
0.79
|
|
49
|
Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects.
|
Curr Med Res Opin
|
2006
|
0.78
|
|
50
|
Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate.
|
Thromb Haemost
|
2013
|
0.78
|
|
51
|
Should vitamin K antagonist therapy be started simultaneously with parenteral anticoagulation: a meta-analysis?
|
Blood Coagul Fibrinolysis
|
2012
|
0.77
|
|
52
|
Bile acids and coagulation factors: paradoxical association in children with chronic liver disease.
|
Eur J Gastroenterol Hepatol
|
2013
|
0.77
|
|
53
|
Optimal reversal of vitamin K antagonists.
|
Thromb Res
|
2005
|
0.77
|
|
54
|
Anticoagulation control with daily low-dose vitamin k to reduce clinically adverse outcomes and international normalized ratio variability: a systematic review and meta-analysis.
|
Pharmacotherapy
|
2013
|
0.77
|
|
55
|
Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
|
Thromb Haemost
|
2005
|
0.77
|
|
56
|
Variability of clinical manifestation of factor VII-deficiency in homozygous and heterozygous subjects of the European F7 gene mutation A294V.
|
Haematologica
|
2008
|
0.76
|
|
57
|
NXY-059 does not affect bleeding time in healthy volunteers: a randomized, double-blind, placebo-controlled, 3-period crossover phase I study.
|
J Clin Pharmacol
|
2007
|
0.76
|
|
58
|
Determinants of bleeding risk in patients on antithrombotic and antifibrinolytic drugs.
|
Semin Thromb Hemost
|
2009
|
0.76
|
|
59
|
Extended anticoagulation in venous thromboembolism.
|
N Engl J Med
|
2013
|
0.76
|
|
60
|
Recombinant FVIIa in children with liver disease.
|
Thromb Res
|
2005
|
0.76
|
|
61
|
Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes.
|
Obstet Gynecol
|
2014
|
0.76
|
|
62
|
The onerous task of comparing treatments in inhibitor patients.
|
Thromb Haemost
|
2007
|
0.75
|
|
63
|
Response to Dr Junqueira.
|
Chest
|
2013
|
0.75
|
|
64
|
Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa-based methods overestimate antithrombin activity in some patients?
|
Blood
|
2002
|
0.75
|
|
65
|
Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism.
|
Br J Haematol
|
2006
|
0.75
|
|
66
|
A step change in oral anticoagulation: lack of coagulation monitoring with ximelagatran.
|
Semin Vasc Med
|
2005
|
0.75
|
|
67
|
Experiences of a low-intensity anticoagulation regimen for extended secondary prevention of venous thromboembolism.
|
Hematol J
|
2002
|
0.75
|
|
68
|
RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
|
Thromb Haemost
|
2016
|
0.75
|
|
69
|
Bleeding events with dabigatran or warfarin in patients with venous thromboembolism.
|
Thromb Haemost
|
2015
|
0.75
|
|
70
|
The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin. A randomised trial.
|
Thromb Haemost
|
2016
|
0.75
|
|
71
|
Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation.
|
Thromb Haemost
|
2016
|
0.75
|
|
72
|
Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. Pooled analysis of RE-COVER and RE-COVER II.
|
Thromb Haemost
|
2017
|
0.75
|
|
73
|
Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding. A risk modelling analysis.
|
Thromb Haemost
|
2016
|
0.75
|
|
74
|
Reply to Dr Lessire et al.
|
Reg Anesth Pain Med
|
2016
|
0.75
|
|
75
|
Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation.
|
J Popul Ther Clin Pharmacol
|
2013
|
0.75
|